Novapharm Research has been recognised as a global leader in the skin asepsis category of infection control for over three decades. The company has an extensive patent portfolio and a series of platform technologies which have been recognised for their technological originality achieving functional advancements throughout the world. Novapharm’s expertise spans formulation, chemistry and microbiology together with dispensing and packaging.

 

Novapharm has powerful technology in hard surface disinfection and the pre-cleaning and re-processing of medical instruments, thus, an end-to-end infection control platform. Novapharm enjoys several accreditations including ISO13485.

 

Novapharm has developed a series of the world’s leading skin asepsis product ranges for our customers, including Microshield, Avagard and Asepti. We have also published multiple papers on microbial control and sat on numerous industry & technical committees.

Novapharm enjoys a broad Patent portfolio as well as a large portfolio of regulatory files and approvals in key global markets and has a strategic focus on work-flow and cost efficiency ‘in use’. There is an ongoing focus on new product pipelines together with a unique capability of adapting to customer technical needs across all business units so as to innovate and develop unique, broad IP based solutions that continue to “raise the bar” by delivering next generation / superior products.